Compare IX & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IX | RMD |
|---|---|---|
| Founded | 1950 | 1989 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5B | 34.0B |
| IPO Year | 1999 | 1996 |
| Metric | IX | RMD |
|---|---|---|
| Price | $36.84 | $238.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $251.99 |
| AVG Volume (30 Days) | 243.9K | ★ 967.2K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.05% | 1.09% |
| EPS Growth | N/A | ★ 9.67 |
| EPS | N/A | ★ 10.43 |
| Revenue | N/A | ★ $2,957,013,000.00 |
| Revenue This Year | $3.66 | $2.59 |
| Revenue Next Year | $5.68 | $6.92 |
| P/E Ratio | ★ $12.93 | $23.25 |
| Revenue Growth | N/A | ★ 13.44 |
| 52 Week Low | $24.19 | $180.27 |
| 52 Week High | $42.39 | $277.67 |
| Indicator | IX | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 66.40 |
| Support Level | $35.68 | $217.41 |
| Resistance Level | $37.04 | $242.40 |
| Average True Range (ATR) | 0.45 | 4.63 |
| MACD | -0.05 | 1.94 |
| Stochastic Oscillator | 43.17 | 85.93 |
ORIX Corp is a diversified financial services company with operations in Corporate Financial Services, Maintenance Leasing, Real Estate, PE Investment and Concession, Environment and Energy, Insurance, Banking and Credit, Aircraft and Ships, ORIX USA, ORIX Europe, Asia, and Australia and engages in various other fee businesses by providing products and services aligned with customer needs to its core customer base of domestic small and medium-sized enterprises. Orix's numerous divisions finance leases of large-ticket items like ships, airplanes, and technology equipment. The company generates the majority of its revenue from Corporate Financial Services and Maintenance Leasing operations and Real Estate operations.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.